Prosecution Insights
Last updated: November 04, 2026
Application No. 17/638,181

An improved process for the preparation of Etelcalcetide Hydrochloride

Final Rejection §103§112
Filed
Feb 24, 2022
Priority
Aug 26, 2019 — IN 201941034285 +1 more
Examiner
NIEBAUER, RONALD T
Art Unit
1658
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Auro Peptides Ltd.
OA Round
4 (Final)
41%
Grant Probability
Moderate
5-6
OA Rounds
0m
Est. Remaining
75%
With Interview

Examiner Intelligence

Grants 41% of resolved cases
41%
Career Allowance Rate
299 granted / 733 resolved
-19.2% vs TC avg
Strong +34% interview lift
Without
With
+34.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 7m
Avg Prosecution
57 currently pending
Career history
805
Total Applications
across all art units

Statute-Specific Performance

§101
7.4%
-32.6% vs TC avg
§103
26.4%
-13.6% vs TC avg
§102
19.5%
-20.5% vs TC avg
§112
29.2%
-10.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 733 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions and Claim Status Applicants’ amendments and arguments filed 9/2/26 are acknowledged. Any objection or rejection from the 6/2/26 office action that is not addressed below is withdrawn based on the amendments and/or arguments. Previously, Group 1 was elected. Claims 8-9 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 3/9/25. Claims 1-7 are being examined. Priority The priority information is found in the filing receipt dated 6/14/22. Specification The amendment filed 12/21/25 is objected to under 35 U.S.C. 132(a) because it introduces new matter into the disclosure. 35 U.S.C. 132(a) states that no amendment shall introduce new matter into the disclosure of the invention. The added material which is not supported by the original disclosure is as follows: The specification has been amended to recite ‘x has a value of 4-5’ specifically with respect to CH3COOH (for example page 3 line 16). The phrase ‘x has a value of 4-5’ could not be located in the original application and the arguments do not point to any location or reasoning for support for the amendment with respect to CH3COOH (arguments related to HCl are not necessarily relevant to arguments about CH3COOH). Applicant is required to cancel the new matter in the reply to this Office Action. Response to Arguments - Specification Applicant's arguments filed 9/2/26 have been fully considered but they are not persuasive. Although applicants argue that the amendments to the specification have been canceled, there is no such amendment of record. Claim Rejections - 35 USC § 112 This rejection is a new rejection necessitated by amendment. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-7 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1d has been amended to refer to ‘using very dilute HCl’. The term “very dilute” in claim 1 is a relative term which renders the claim indefinite. The term “very dilute” is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. In the instant case, it is unclear what amounts or concentrations would be considered very dilute. None of the dependent claims clarify the claim scope. Although unclear the claims have been given the broadest reasonable interpretation consistent with the specification. Response to Arguments - 112 Applicant's arguments filed 9/2/26 have been fully considered but they are not persuasive with respect to the rejection set forth above. Although applicants argue that the claims have been amended, the amended claims are addressed above. Although applicants argue that very dilute would be understood in terms of sufficiently low to accomplish salt exchange yet dilute enough to prevent the acid-catalyzed hydrolysis or degradation of the peptide, no such definition could be found in the instant specification. Although applicant can be their own lexicographer, the applicant must clearly set forth a special definition (MPEP 2111.01 IV). Claim Rejections - 35 USC § 103 Claims were previously rejected based on the references cited below. Since the claims have been amended, the rejection is updated to correspond to the instant claims. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1-7 is/are rejected under 35 U.S.C. 103 as being unpatentable over Bezemer et al. (WO 2015/154031; ‘Bezemer’) in view of Gunnoo et al. (‘Reviving old protecting group chemistry for site-selective peptide-protein conjugation’ ChemComm Communication v54 2018 pages 11929-11932; ‘Gunnoo’) in view of Cui et al. (US 2018/0079777; ‘Cui’) in view of Laidler et al. (US 2015/0110820; ‘Laidler’) in view of Mi et al. (CN 105504012 04-2016). Mi et al. (CN 105504012 04-2016) is not in the English language. A copy of a translated version (Translation of CN 105504012 09-2014 Mi et al., 9 pages) is included and all references herein (unless otherwise specified) will be to the translated version (MiTranslation). Bezemer teach methods for preparing AMG 416 (abstract) specifically the hydrocholoride salt of AMG 416 (section 0005). Bezemer teach in figure 2 the structure of the protected peptide on the resin specifically where Cys contains a Trt group and each Arg contains a Pbf group (section 0026 and figure 2 and claim 1). Bezemer teach deprotection with 2,2,2-trifluoroacetic acid (TFA) to result in a Cys modified product (figure 3 and figure 3 caption section 0027). Bezemer teach activating the side chain of the D-Cys residue (claim 1). Bezemer teach reaction with L-Cys to form a disulfide containing salt form (figure 4 and figure 4 caption sections 0014 and 0028). Bezemer teach that purification of the intermediate prior to conjugation with Cys can increase efficiency and decrease cost (section 0072). Bezemer teach the formation of the HCl salt form (figure 5 and figure 5 caption section 0029). Bezemer specifically recognizes a deprotection and cysteine activation step which includes water, TFA and TIPS (section 0066). Bezemer teach that the salt can be purified by HPLC (section 0068). Bezemer teach that the TFA salt can be converted to the hydrochloride salt by any means known in the art (section 0070). Bezemer teach carrying out a salt exchange procedure which are well known in the art (section 0007). Bezemer shows the use of HCl to convert to the HCl salt (figure 5). Bezemer teach that pharmaceutically acceptable salts include acetate (section 0044). Bezemer teach that the TFA salt may be converted to the pharmaceutically acceptable salt such as hydrochloride (section 0070). Bezemer teach purification by preparative chromatography (section 0097). Bezemer teach using HPLC to obtain fractions of the desired purity (section 0097). Bezemer does not teach Scm as in claim 1b. Gunnoo teach a simple strategy for conjugation using peptides with a Cys(Scm) protecting group which is described as efficient and site-selective and generally applicable for disulfide formation (abstract). Gunnoo teach an ease to introducing Cys(Scm) into peptides (last paragraph on page 11929) and specifically teach the use of the chloride form (scheme 2). Gunnoo teach the use of DTT to obtain a free thiol (page 11930 first complete paragraph). Gunnoo concludes that the Scm group can be used as an activating group for disulfide formation (page 11931 last paragraph). Cui teach preparing etelcalcetide (abstract). Cui teach the use of hydrates and salts (section 0064) and specifically teach cysteine hydrochloride hydrate (section 0129). Cui teach that any suitable protecting group may be used to protect D-Cys (section 0104). Cui teach that the TFA salt (acetate salt) is converted to a pharmaceutically acceptable salt such as hydrocholoride salt (section 0006). Cui expressly refers to the 4HCl form (section 0108). Laidler recognizes that the trifluoroacetate salt form of a peptide is not the most acceptable form and that acetate is considered to be a more acceptable form (sections 0008 and 0015). Laidler recognizes that acetic acid is a weaker acid than trifluoroacetic acid (section 0015). MiTranslation teach the preparation of velcalcetide acetate peptide by using HPLC and acetic acid and acetonitrile (embodiment 12 connecting paragraph pages 7-8). Page number 3 (section 0003) of the untranslated Mi document shows the structure of velcalcetide. It would have been obvious to one of ordinary skill in the art before the effective filing date to modify the teachings of Bezemer because Bezemer teach the synthesis of a specific compound with a disulfide and teach activating the side chain of the D-Cys residue (claim 1). Bezemer teach that purification of the intermediate prior to conjugation with Cys can increase efficiency and decrease cost (section 0072). Since Gunnoo teach a simple strategy for conjugation using peptides with a Cys(Scm) protecting group which is described as efficient and site-selective and generally applicable for disulfide formation (abstract) one would have been motivated to use the Scm group. Since Bezemer teach that pharmaceutically acceptable salts include acetate (section 0044) and teach that the salt may be converted to the pharmaceutically acceptable salt such as hydrochloride (section 0070) one would have been motivated to do such by using acetic acid for formation of the acetate. Further, Laidler recognizes that the trifluoroacetate salt form of a peptide is not the most acceptable form (sections 0008 and 0015) and MiTranslation teach the preparation of velcalcetide acetate peptide by using HPLC and acetic acid and acetonitrile (embodiment 12 connecting paragraph pages 7-8) (where velcalcetide is of the same sequence of etelcalcetide – see section 0003 on page 3 of the untranslated Mi document). Thus one would have been motivated to use known techniques to prepare the acetate form. Bezemer teach reaction with L-Cys to form a disulfide containing salt form (figure 4 and figure 4 caption sections 0014 and 0028) and Cui specifically teach cysteine hydrochloride hydrate (section 0129) for synthesis of the same peptide so one would have been motivated to use such form. One would have had a reasonable expectation of success since Cui teach that any suitable protecting group may be used to protect D-Cys (section 0104). Further, the other agents and steps were known. In relation to formula II as recited in claim 1, Bezemer teach in figure 2 the structure of the protected peptide on the resin specifically where Cys contains a Trt group (section 0026 and figure 2 and claim 1). In relation to step a of claim 1, Bezemer teach deprotection with 2,2,2-trifluoroacetic acid (TFA) to result in a Cys modified product (figure 3 and figure 3 caption section 0027). In relation to step b of claim 1, Bezemer teach activating the side chain of D-Cys (claim 1). Gunnoo teach an ease to introducing Cys(Scm) into peptides (last paragraph on page 11929) and specifically teach the use of the chloride form (scheme 2). Bezemer specifically recognizes a deprotection and cysteine activation step which includes water, TFA and TIPS (section 0066). In relation to step c of claim 1, MiTranslation teach the preparation of velcalcetide acetate peptide by using HPLC and acetic acid and acetonitrile (embodiment 12 connecting paragraph pages 7-8) (where velcalcetide is of the same sequence of etelcalcetide – see section 0003 on page 3 of the untranslated Mi document). Bezemer teach reaction with L-Cys to form a disulfide containing salt form (figure 4 and figure 4 caption sections 0014 and 0028). Bezemer teach the formation of the HCl salt form (figure 5 and figure 5 caption section 0029). Bezemer specifically recognizes a deprotection and cysteine activation step which includes water, TFA and TIPS (section 0066). Bezemer teach that the salt can be purified by HPLC (section 0068). Bezemer teach that pharmaceutically acceptable salts include acetate (section 0044). In relation to step d of claim 1, Bezemer teach that the TFA salt may be converted to the pharmaceutically acceptable salt such as hydrochloride (section 0070). Cui expressly refers to the 4HCl form (section 0108). Bezemer teach that the TFA salt can be converted to the hydrochloride salt by any means known in the art (section 0070). Bezemer teach carrying out a salt exchange procedure which are well known in the art (section 0007). Bezemer shows the use of HCl to convert to the HCl salt (figure 5). Bezemer teach that pharmaceutically acceptable salts include acetate (section 0044). Bezemer teach that the TFA salt may be converted to the pharmaceutically acceptable salt such as hydrochloride (section 0070). Bezemer teach purification by preparative chromatography (section 0097). Bezemer teach using HPLC to obtain fractions of the desired purity (section 0097). In relation to claim 2, Bezemer teach in figure 2 the structure of the protected peptide on the resin specifically where Cys contains a Trt group (section 0026 and figure 2 and claim 1). Further, Gunnoo teach a simple strategy for conjugation using peptides with a Cys(Scm) protecting group which is described as efficient and site-selective and generally applicable for disulfide formation (abstract) which utilizes an Acm group (scheme 2). In relation to claims 3-5, Bezemer specifically recognizes a deprotection and cysteine activation step which includes water, TFA and TIPS (section 0066). Gunnoo teach the use of DTT to obtain a free thiol (page 11930 first complete paragraph). In relation to claim 6, MiTranslation teach the preparation of velcalcetide acetate peptide by using HPLC and acetic acid and acetonitrile (embodiment 12 connecting paragraph pages 7-8) (where velcalcetide is of the same sequence of etelcalcetide – see section 0003 on page 3 of the untranslated Mi document). Bezemer teach HPLC purification using an acetate and acetonitrile (section 00100). Since Bezemer teach that pharmaceutically acceptable salts include acetate (section 0044) and teach that the salt may be converted to the pharmaceutically acceptable salt such as hydrochloride (section 0070) one would have been motivated to do such by using acetic acid for formation of the acetate. In relation to claim 7, Bezemer teach reaction with L-Cys to form a disulfide containing salt form (figure 4 and figure 4 caption sections 0014 and 0028) and Cui specifically teach cysteine hydrochloride hydrate (section 0129). Response to Arguments - 103 Applicant's arguments filed 9/2/26 have been fully considered but they are not persuasive with respect to the rejection set forth above. Although applicants argue that Gunnoo is non-analogous art because it is not drawn to industrial scale synthesis of a peptide, it is first noted that claim 1 does not require industrial scale. Gunnoo uses the word ‘peptide’ 55 times and the title of Gunnoo relates to chemistry for peptides. One would recognize peptide chemistry as relevant to peptide synthesis. Although applicants argue that Gunnoo is not reasonably pertinent, MPEP 2141.01(a) I recites “In order for a reference to be "reasonably pertinent" to the problem, it must "logically [] have commended itself to an inventor's attention in considering his problem.". In the instant case, claim 1b requires reacting and modifying a cysteine side chain and eventual contact with Cys to form a disulfide bond (claim 1c). Gunnoo teach a simple strategy for conjugation using peptides with a Cys(Scm) protecting group which is described as efficient and site-selective and generally applicable for disulfide formation (abstract). Although applicants argue that the similarity of Bezemer with the present invention is limited to solid phase peptide synthesis of etelcalcetide, such similarity is significant because as denoted in the instant title the invention relates to preparation of etelcalcetide. Although applicants argue about the teachings of Bezemer or Gunnoo alone, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See In re Keller, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); In re Merck & Co., 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986). Although applicants argue about the teachings of Cui or Laidler or Mi alone, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See In re Keller, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); In re Merck & Co., 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986). Although applicants argue about a reasonable expectation of success based on Bezemer, the instant rejection is not based on Bezemer alone. Gunnoo teach a simple strategy for conjugation using peptides with a Cys(Scm) protecting group which is described as efficient and site-selective and generally applicable for disulfide formation (abstract). Gunnoo teach an ease to introducing Cys(Scm) into peptides (last paragraph on page 11929) and specifically teach the use of the chloride form (scheme 2). Gunnoo teach the use of DTT to obtain a free thiol (page 11930 first complete paragraph). Gunnoo concludes that the Scm group can be used as an activating group for disulfide formation (page 11931 last paragraph). One would have had a reasonable expectation of success since Cui teach that any suitable protecting group may be used to protect D-Cys (section 0104). Further, the other agents and steps were known. Although applicants argue that Bezemer teaches away by referring to Spy intermediates and not using Scm, the instant claims do not relate to using a Spy intermediate. Bezemer teach in figure 2 the structure of the protected peptide on the resin specifically where Cys contains a Trt group (section 0026 and figure 2 and claim 1). Gunnoo teach a simple strategy for conjugation using peptides with a Cys(Scm) protecting group which is described as efficient and site-selective and generally applicable for disulfide formation (abstract). Gunnoo teach an ease to introducing Cys(Scm) into peptides (last paragraph on page 11929) and specifically teach the use of the chloride form (scheme 2). Gunnoo teach the use of DTT to obtain a free thiol (page 11930 first complete paragraph). Gunnoo concludes that the Scm group can be used as an activating group for disulfide formation (page 11931 last paragraph). Bezemer teach that purification of the intermediate prior to conjugation with Cys can increase efficiency and decrease cost (section 0072). Thus, Bezemer does not teach purification solely of the final product as asserted by applicant. In response to applicant's argument that the examiner's conclusion of obviousness is based upon improper hindsight reasoning, it must be recognized that any judgment on obviousness is in a sense necessarily a reconstruction based upon hindsight reasoning. But so long as it takes into account only knowledge which was within the level of ordinary skill at the time the claimed invention was made, and does not include knowledge gleaned only from the applicant's disclosure, such a reconstruction is proper. See In re McLaughlin, 443 F.2d 1392, 170 USPQ 209 (CCPA 1971). Although applicants argue that the claims require purification of a Scm-activated intermediate, Bezemer teach that purification of the intermediate prior to conjugation with Cys can increase efficiency and decrease cost (section 0072). Gunnoo teach a simple strategy for conjugation using peptides with a Cys(Scm) protecting group which is described as efficient and site-selective and generally applicable for disulfide formation (abstract). Gunnoo teach an ease to introducing Cys(Scm) into peptides (last paragraph on page 11929) and specifically teach the use of the chloride form (scheme 2). Gunnoo teach the use of DTT to obtain a free thiol (page 11930 first complete paragraph). Gunnoo concludes that the Scm group can be used as an activating group for disulfide formation (page 11931 last paragraph). Although applicants argue about hindsight, it must be recognized that any judgment on obviousness is in a sense necessarily a reconstruction based upon hindsight reasoning. But so long as it takes into account only knowledge which was within the level of ordinary skill at the time the claimed invention was made, and does not include knowledge gleaned only from the applicant's disclosure, such a reconstruction is proper. See In re McLaughlin, 443 F.2d 1392, 170 USPQ 209 (CCPA 1971). Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to RONALD T NIEBAUER whose telephone number is (571)270-3059. The examiner can normally be reached M - F 6:30 - 2:30 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Melissa Fisher can be reached at 571-270-7430. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. RONALD T. NIEBAUER Primary Examiner Art Unit 1658 /RONALD T NIEBAUER/Examiner, Art Unit 1658
Read full office action

Prosecution Timeline

Show 1 earlier event
May 05, 2025
Non-Final Rejection mailed — §103, §112
Jul 25, 2025
Response Filed
Sep 23, 2025
Final Rejection mailed — §103, §112
Jan 21, 2026
Request for Continued Examination
Feb 02, 2026
Response after Non-Final Action
Jun 02, 2026
Non-Final Rejection mailed — §103, §112
Sep 02, 2026
Response Filed
Oct 19, 2026
Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12746220
PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF ISCHEMIC CARDIOVASCULAR DISEASE
6y 4m to grant Granted Sep 29, 2026
Patent 12723063
GIPR-AGONIST COMPOUNDS
2y 8m to grant Granted Sep 01, 2026
Patent 12678511
PEPTIDE AND USE THEREOF
4y 9m to grant Granted Jul 14, 2026
Patent 12673135
COLLAGEN-BASED MENISCUS IMPLANTS
4y 6m to grant Granted Jul 07, 2026
Patent 12668610
COMPOUNDS FOR DRUG DELIVERY ACROSS BLOOD-BRAIN BARRIER
3y 6m to grant Granted Jun 30, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
41%
Grant Probability
75%
With Interview (+34.1%)
3y 7m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 733 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month